- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05834569
Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
September 3, 2023 updated by: Kim, Heezoo, Korea University Guro Hospital
The Impact of Intravenous Administration of Perioperative Acetaminophen and Ibuprofen Combination (Maxigesic®) on Postoperative Delirium in Elderly Patients Undergoing Minimally Invasive Lung Segmentectomy or Lobectomy
The primary aim of this interventional study is to investigate the impact of perioperative administration of Maxigesic (combination of acetaminophen and ibuprofen) on delirium after minimally invasive lung surgery in elderly patients.
The Maxigesic group receives a total of 5 doses of Maxigesic (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthesia induction.
The control group receives the same volume of normal saline.
Researchers compare the incidence and severity of postoperative delirium for 5 days after surgery.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
176
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hye Bin Kim, MD, PhD
- Phone Number: 82-10-9183-5617
- Email: aneshbkim@gmail.com
Study Contact Backup
- Name: Heezoo KIM, MD, PhD
- Phone Number: 82-2-2626-1437
- Email: kimheezoo@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 08308
- Recruiting
- Korea University Guro Hospital
-
Contact:
- Hye Bin Kim, MD, PhD
- Phone Number: 82-2-2626-1437
- Email: anesbhkim@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged 65 years or older undergoing minimally invasive lung lobectomy or segmentectomy
Exclusion Criteria:
- Hypersensitivity to the main ingredients and additives of Maxigesic
- Hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
- Alcoholism / Alcohol intoxication
- Severe hematological abnormalities
- Bleeding tendency (e.g., Spontaneous bleeding)
- Severe hepatic dysfunction (AST, AST ≥2.5 * upper normal limit(UNL) or Total bilirubin ≥3.0 mg/dl)
- Severe renal dysfunction (eGFR <30 ml/min/1.73m2 or Dialysis)
- Severe heart failure (Left ventricle ejection fraction <30%)
- Uncontrolled hypertension(HTN) (Systolic blood pressure >180 mmHg)
- Symptomatic asthma in need of treatment
- Anticoagulants or antiplatelet agents are maintained for up to 5 days before surgery
- Barbiturates or tricyclic antidepressants (TCAs)
- High-dose methotrexate (MTX) for cancer treatment
- Preoperative cognitive impairment, dementia, or delirium
- Inability to understand the research and instructions for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group
|
Patients in the control group will be administered equal amounts of normal saline at the same time points.
|
Experimental: Maxigesic group
|
Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of postoperative delirium(POD)
Time Frame: From immediately after surgery to 5 days after surgery
|
Confusion assessment method(CAM)/Confusion Assessment Method for the ICU (CAM-ICU) or delirium record on electrical medical record(EMR) will be used for the evaluation of POD.
|
From immediately after surgery to 5 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of POD
Time Frame: From immediately after surgery to 5 days after surgery
|
CAM/CAM-ICU or delirium record on EMR will be used to estimate the duration of POD.
|
From immediately after surgery to 5 days after surgery
|
Preoperative cognition
Time Frame: 1 day before surgery
|
Mini-mental state examination(MMSE) will be used to evaluate the participants' preoperative cognition.
(*MMSE is measured on 0-30 scale, and the lower the score, the more cognitively impaired the patient is.)
|
1 day before surgery
|
Preoperative cognition
Time Frame: 1 day before surgery
|
Montreal cognitive assessment(MoCA) will be used to evaluate the participants' preoperative cognition.
(*MoCA is measured on 0-30 scale, and the lower the score, the more cognitively impaired the patient is.)
|
1 day before surgery
|
Preoperative frailty
Time Frame: 1 day before surgery
|
Clinical frailty scale(CFS) will be utilized to assess the preoperative frailty (*CFS is used to determine comprehensive geriatric assessment.
It is measured on 1-9 scale, and the higher the scale, the more frail the patient is.)
|
1 day before surgery
|
Postoperative pain
Time Frame: Immediately after surgery to postoperative 48 hours
|
Numerical rating scale (NRS) or Visual analogue scale (VAS) will be used to determine the postoperative pain severity (*NRS and VAS are measured on a 0-10 scale, and the higher the score, the more severe the patient's pain.
If the patient can verbalize their pain, use the NRS; otherwise, use the VAS to assess pain).
|
Immediately after surgery to postoperative 48 hours
|
Consumption of opioids
Time Frame: Immediately after surgery to postoperative 48 hours
|
Opioid consumption is measured by converting them into morphine equivalents.
|
Immediately after surgery to postoperative 48 hours
|
Postoperative nausea, vomiting
Time Frame: Immediately after surgery to postoperative 48 hours
|
Nausea is measured by scoring on a scale of 0-10.
The higher the score, the more severe the symptom.
Whether the patients vomit or not is observed and recorded.
|
Immediately after surgery to postoperative 48 hours
|
ICU stay
Time Frame: Immediately after surgery to ICU discharge(usually within about 5 days after surgery)
|
Determine how many days the participant stays in the ICU.
|
Immediately after surgery to ICU discharge(usually within about 5 days after surgery)
|
Hospital stay
Time Frame: Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Determine how many days the participant stays in the hospital.
|
Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Postoperative complications
Time Frame: Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Investigate all kinds of complications that occur after surgery.
|
Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Drug side effects
Time Frame: Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Investigate complications suspected to be side effects caused by the study drug.
|
Immediately after surgery to hospital discharge(usually within about 30 days after surgery)
|
Severity of POD
Time Frame: From immediately after surgery to 5 days after surgery
|
CAM-S(severity) will be utilized to assess the severity of POD.
(*CAM-S is measured on 0-7 (short form) and 0-19 (long form) scale, and the higher the score, the greater the POD severity.)
|
From immediately after surgery to 5 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Heezoo Kim, MD, PhD, Korea University Guro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
March 7, 2023
First Submitted That Met QC Criteria
April 17, 2023
First Posted (Actual)
April 28, 2023
Study Record Updates
Last Update Posted (Actual)
September 6, 2023
Last Update Submitted That Met QC Criteria
September 3, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Delirium
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
- 2023GR0023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The investigators have no plans yet to share individual participant data (IPD) with other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicRecruitingDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Menoufia UniversityCompleted
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Active, not recruitingDelirium | Delirium on Emergence | Hearing Loss | Hearing Loss, High-Frequency | Hearing Loss, Sensorineural | Delirium, Cause Unknown | Hearing Loss, Bilateral | Hearing Disability | Delirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional State | Delirium With... and other conditionsUnited States
-
Chinese PLA General HospitalBeijing Tiantan HospitalRecruiting
-
Charite University, Berlin, GermanyBARMERRecruitingDelirium in Old AgeGermany
-
Mayo ClinicCompletedPost-Operative DeliriumUnited States
-
University Hospital, Basel, SwitzerlandInnosuisse - Swiss Innovation AgencyRecruitingPostoperative Delirium (POD)Switzerland
Clinical Trials on Acetaminophen and Ibuprofen
-
Washington University School of MedicineCompletedPain, Postoperative | Tonsillitis | Tonsillar HypertrophyUnited States
-
Reckitt Benckiser LLCPremier Research Group plc; Aptuit Inc.CompletedPost-operative PainUnited States
-
University of South AlabamaTerminatedBronchopulmonary Dysplasia | Patent Ductus Arteriosus | Preterm InfantUnited States
-
Ullevaal University HospitalUniversity of OsloCompleted
-
University of CatanzaroCompleted
-
Alexander Payatakes, M.D.TerminatedTrigger Finger | Carpal Tunnel | De Quervain Disease | Ganglion CystUnited States
-
University of FloridaWithdrawnPatent Ductus Arteriosus
-
Cumberland PharmaceuticalsCompleted
-
PfizerCompletedPost-surgical Pain Following Extraction of Molar TeethUnited States